oasis 4 semaglutide 25 mg Oral Wegovy approved for obesity management by FDA on December 23, 2025 Formulation: High‑dose oral (25 daily) — previously only available as weekly injections. Indication: Adults with obesity (BMI ≥30) oasis-4 semaglutide oasis 4 trial

It is recommended to inject semaglutide in the same area as insulin injections, but not directly next to each other

Therefore, a multimodal approach may be necessary when treating COVID-19 in elderly patients or in those with preexisting conditions

Appetite and energy effects can appear within a few weeks, but meaningful weight change usually takes two to three months at the target dose

Body composition continues changing even when weight stalls

Ultimately, we hope our preliminary data will encourage dermatologists to consider weight loss medication as an adjunct to existing HS treatments and inspire further research in this area aimed at improving outcomes for people living with this challenging condition, said Dr